This study will identify areas for improvement in supporting the lives of people with stage 3 or 4 ovarian cancer. Read more
A study of genetic markers in nearly 15,000 women with endometriosis and more than 25,000 women with ovarian cancer has found what researchers say is a causal link between the two conditions. Read more
A study of the new Tie2 blood test in women having bevacizumab for ovarian cancer (VALTIVE1). Read more
NICE has confirmed it's recommendation for the PARP inhibitor niraparib as an option for treating relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer in adults. Read more
PROTECTOR is a research study for women at increased risk of ovarian cancer. It aims to assess the impact on women of a new two-step surgery to prevent ovarian cancer. Read more
Niraparib is currently being evaluated by the National Institute for Health and Care Excellence (NICE) for use in routine commissioning – meaning it becomes routinely available on the NHS. Read more
The Joint Committee on Vaccination and Immunisation (JCVI) has recommended that people with severely weakened immune systems should have a third vaccine dose as part of their primary Covid-19 vaccination schedule. Read more
A large scale ovarian cancer screening trial - UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) – has not been able to demonstrate that annual screening saves lives. Read more
The National Institute for Health and Care Excellence (NICE) recently approved the drugs olaparib plus bevacizumab (Avastin) for use within the Cancer Drugs Fund (CDF). Read more
The results of two research studies have shown that overall survival can be improved following secondary surgery for ovarian cancer. Read more
One patient, diagnosed with ovarian cancer, saw her tumours shrink after combination treatment with berzosertib and chemotherapy. Read more
A study funded by Cancer Research UK and The Eve Appeal provided volunteers with a personalised risk estimate of developing ovarian cancer. The volunteers' ovarian cancer worry and general cancer risk perception decreased over six months. Read more
A new blood test that can detect more than 50 types of cancer, including ovarian cancer, has been revealed by researchers in the latest study to offer hope for early detection. Read more
Researchers discovered that genetic mutations which fuel the growth of tumours often occur years before the cancer is discovered. Read more
The new tool can identify cases of ovarian cancer which are difficult to diagnose using standard methods. Read more
Peripheral neuropathy is a common side effect of taxol chemotherapy, and a less common side effect of carboplatin, both used to treat ovarian cancer. Read more
Researchers at Cardiff University have discovered a part of our immune system which could be used to treat all cancers, including ovarian cancer. Read more
News from the ESMO (European Society for Medical Oncology) 2019 conference Read more
The randomised trial of a drug called trametinib – previously used to treat melanoma – was shown to have an increased response rate compared with standard treatments. Read more
Researchers from Queen’s University Belfast have developed a test that may be able to detect ovarian cancer up to two years earlier than current approaches. Read more
The new drug can get inside tumour cells and has shown promise in patients with six different advanced, drug-resistant cancers. Read more
The test scans the shapes of tumour cells to pick out women with especially aggressive ovarian cancer, so treatment can be tailored to their needs. Read more
It is possible that preventing the webs from being formed could limit the spread and avoid the need for the omentum to be surgically removed Read more
Weight loss drug Orlistat may help women with treatment-resistant ovarian cancer respond to chemotherapy again. Read more